IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
IN8bio, Inc. INAB
$0.90
▼ -4.27%
($-0.04)
⬇️ Below Yest. Low
🎈 Low Float
Open
$0.98
Prev Close
$0.94
Day Range
$0.90 – $0.99
52W Range
$0.80 – $2.73
Market Cap
$10.16M
Beta
0.34
EPS (TTM)
$-2.05
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-11-12 |
| Shares Out. | 9,860,000 |
| Website | in8bio.com ↗ |
| Phone | 13026587581 |
| Employees | 20 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$4.8M |
| Free Cash Flow | -$14.6M |
| Total Assets | $21.7M |
| Total Liabilities | $3.4M |
| Equity | $18.4M |
About IN8bio, Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
IN8bio, Inc. is a publicly traded company under the ticker symbol INAB on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
9 analysts (2026-11-01)